Trials / Completed
CompletedNCT01688960
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) in combination with aflibercept ("ziv-aflibercept" in the U.S.)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nesvacumab (REGN910/ SAR307746) | Dose level 1 |
| DRUG | nesvacumab (REGN910/ SAR307746) | Dose level 2 |
| DRUG | nesvacumab (REGN910/ SAR307746) | Dose level 3 |
| DRUG | aflibercept (ziv-aflibercept) | Dose level 1 |
| DRUG | aflibercept (ziv-aflibercept) | Dose level 2 |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2012-09-20
- Last updated
- 2015-03-17
Locations
6 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01688960. Inclusion in this directory is not an endorsement.